PROSTVAC 在无症状或轻微症状转移性去势抵抗性前列腺癌中的 III 期试验
第三次中期分析因无效性标准而提前终止,PROSTVAC 单药组和联合组均未改善总生存期(中位 OS:34.4 个月和 33.2 个月 vs 安慰剂组 34.3 个月),6 个月无事件生存率也相似。PROSTVAC 安全且耐受性良好,但未影响 OS 或无事件生存。
要点
- 第三次中期分析达到无效性标准,试验提前终止。
- PROSTVAC 单药和联合粒细胞-巨噬细胞集落刺激因子均未改善中位 OS。
- 6 个月无事件生存率在三组间相似,安全性无显著差异。
核心结论
- PROSTVAC 安全且耐受性良好,但对转移性去势抵抗性前列腺癌的总生存期和无事件生存均无影响。
- 联合治疗目前正在临床试验中探索。
研究设计与样本
- III 期优越性试验,将患者随机分配至 PROSTVAC 单药组(V 组,n=432)、PROSTVAC 联合粒细胞-巨噬细胞集落刺激因子组(VG 组,n=432)或安慰剂组(P 组,n=433)。
- 按前列腺特异性抗原(<50 ng/mL vs ≥50 ng/mL)和乳酸脱氢酶(<200 vs ≥200 U/L)分层。
- 主要终点为总生存期;次要终点为 6 个月时无事件存活(即无影像学进展、疼痛进展、开始化疗或死亡)和安全性。
- 计划进行三次中期分析。
主要发现
- 第三次中期分析时达到无效性标准,试验提前终止。
- 中位 OS:V 组 34.4 个月(HR 1.01,95%CI 0.84-1.20,P=.47),VG 组 33.2 个月(HR 1.02,95%CI 0.86-1.22,P=.59),P 组 34.3 个月。
- 6 个月无事件存活率:V 组 29.4%(OR 0.96,95%CI 0.71-1.29),VG 组 28.0%(OR 0.89,95%CI 0.66-1.20),P 组 30.3%。
- 不良事件在治疗组和安慰剂组间相似,最常见为注射部位反应(62%-72%)和疲乏(21%-24%)。
- 心律失常是最常见的心脏相关事件(1.4%-3.5%),未报告心肌炎或心包炎;严重治疗相关事件在所有患者中<1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PROSTVAC, a viral vector-based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further investigated those findings. PATIENTS AND METHODS: Patients were randomly assigned to PROSTVAC (Arm V; n = 432), PROSTVAC plus granulocyte-macrophage colony-stimulating factor (Arm VG; n = 432), or placebo (Arm P; n = 433), stratified by prostate-specific antigen (less than 50 ng/mL v 50 ng/mL or more) and lactate dehydrogenase (less than 200 v 200 U/L or more). Primary end point was OS. Secondary end points were patients alive without events (AWE)-namely, radiographic progression, pain progression, chemotherapy initiation, or death-at 6 months and safety. The study design was a superiority trial of PROSTVAC (Arm V or Arm VG) versus Arm P. Three interim analyses were planned. RESULTS: At the third interim analysis, criteria for futility were met and the trial was stopped early. Neither active treatment had an effect on median OS (Arm V, 34.4 months; hazard ratio, 1.01; 95% CI, 0.84 to 1.20; P = .47; Arm VG, 33.2 months; hazard ratio, 1.02; 95% CI, 0.86 to 1.22; P = .59; Arm P, 34.3 months). Likewise, AWE at 6 months was similar (Arm V, 29.4%; odds ratio, 0.96; 95% CI, 0.71 to 1.29; Arm VG, 28.0%; odds ratio, 0.89; 95% CI, 0.66 to 1.20; placebo, 30.3%). Adverse events were similar for the treatment and placebo groups, with the most common being injection site reactions (62% to 72%) and fatigue (21% to 24%). Arrhythmias were the most common cardiac-related events (1.4% to 3.5%). There were no reports of either myocarditis or pericarditis. Serious treatment-related events occurred in less than 1% of all patients. CONCLUSION: Whereas PROSTVAC was safe and well tolerated, it had no effect on OS or AWE in metastatic castration-resistant prostate cancer. Combination therapy is currently being explored in clinical trials.
引用
- Gulley JL, Borre M, Vogelzang NJ, et al. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019. PMID: 30817251. doi:10.1200/JCO.18.02031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。